Machine learning-based prediction of surgical benefit in borderline resectable and locally advanced pancreatic cancer

被引:0
|
作者
Zhang, Leiming [1 ,2 ]
Yu, Zehao [2 ]
Jin, Rong [1 ,2 ]
Yang, Xuanang [2 ]
Ying, Dongjian [1 ]
机构
[1] Ningbo Univ, Affiliated Lihuili Hosp, Dept Minimally Invas Surg, Ningbo, Zhejiang, Peoples R China
[2] Ningbo Univ, Hlth Sci Ctr, Ningbo, Zhejiang, Peoples R China
关键词
Machine learning; Borderline resectable pancreatic cancer; Locally advanced pancreatic cancer; Postoperative; Model prediction; DUCTAL ADENOCARCINOMA; SURGERY; 5-FLUOROURACIL; CHEMOTHERAPY; FOLFIRINOX; CONSENSUS; THERAPY;
D O I
10.1007/s00432-023-05071-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionSurgery represents a primary therapeutic approach for borderline resectable and locally advanced pancreatic cancer (BR/LAPC). However, BR/LAPC lesions exhibit high heterogeneity and not all BR/LAPC patients who undergo surgery can derive beneficial outcomes. The present study aims to employ machine learning (ML) algorithms to identify those who would obtain benefits from the primary tumor surgery.MethodsWe retrieved clinical data of patients with BR/LAPC from the Surveillance, Epidemiology, and End Results (SEER) database and classified them into surgery and non-surgery groups based on primary tumor surgery status. To eliminate confounding factors, propensity score matching (PSM) was employed. We hypothesized that patients who underwent surgery and had a longer median cancer-specific survival (CSS) than those who did not undergo surgery would certainly benefit from surgical intervention. Clinical and pathological features were utilized to construct six ML models, and model effectiveness was compared through measures such as the area under curve (AUC), calibration plots, and decision curve analysis (DCA). We selected the best-performing algorithm (i.e., XGBoost) to predict postoperative benefits. The SHapley Additive exPlanations (SHAP) approach was used to interpret the XGBoost model. Additionally, data from 53 Chinese patients prospectively collected was used for external validation of the model.ResultsAccording to the results of the tenfold cross-validation in the training cohort, the XGBoost model yielded the best performance (AUC = 0.823, 95%CI 0.707-0.938). The internal (74.3% accuracy) and external (84.3% accuracy) validation demonstrated the generalizability of the model. The SHAP analysis provided explanations independent of the model, highlighting important factors related to postoperative survival benefits in BR/LAPC, with age, chemotherapy, and radiation therapy being the top three important factors.ConclusionBy integrating of ML algorithms and clinical data, we have established a highly efficient model to facilitate clinical decision-making and assist clinicians in selecting the population that would benefit from surgery.
引用
收藏
页码:11857 / 11871
页数:15
相关论文
共 50 条
  • [31] Impact of resection margin status on recurrence and survival in patients with resectable, borderline resectable, and locally advanced pancreatic cancer
    Rompen, Ingmar F.
    Marchetti, Alessio
    Levine, Jonah
    Swett, Benjamin
    Galimberti, Veronica
    Han, Jane
    Riachi, Mansour E.
    Habib, Joseph R.
    Imam, Rami
    Kaplan, Brian
    Sacks, Greg D.
    Cao, Wenqing
    Wolfgang, Christopher L.
    Javed, Ammar A.
    Hewitt, D. Brock
    SURGERY, 2025, 180
  • [32] Effect of Radiotherapy in Neoadjuvant Treatment of Borderline Resectable and Locally Advanced Pancreatic Cancer
    Tang, Peng
    Zhang, Junfeng
    Zhou, Qiang
    Yi, Wenmin
    Wang, Huaizhi
    PANCREAS, 2025, 54 (03) : e246 - e254
  • [33] Survival after vascular resections in patients with borderline resectable or locally advanced pancreatic head cancer: A systematic review
    Papakonstantinou, Menelaos
    Fiflis, Stylianos
    Giakoustidis, Alexandros
    Christodoulidis, Grigorios
    Myriskou, Athanasia
    Louri, Eleni
    Papalavrentios, Lavrentios
    Papadopoulos, Vasileios N.
    Giakoustidis, Dimitrios
    ANNALS OF HEPATO-BILIARY-PANCREATIC SURGERY, 2024, 28 (04) : 423 - 432
  • [34] Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
    Sulciner, Megan L.
    Ashley, Stanley W.
    Molina, George
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (16)
  • [35] Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy
    Wijetunga, Asanka R.
    Chua, Terence C.
    Nahm, Christopher B.
    Pavlakis, Nick
    Clarke, Stephen
    Chan, David L.
    Diakos, Connie
    Maloney, Sarah
    Ashrafi-Zadeh, Amir
    Kneebone, Andrew
    Hruby, George
    Jamieson, Nigel B.
    Gill, Anthony
    Mittal, Anubhav
    Samra, Jaswinder S.
    EJSO, 2021, 47 (10): : 2543 - 2550
  • [36] Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy
    Barugola, Giuliano
    Partelli, Stefano
    Crippa, Stefano
    Capelli, Paola
    D'Onofrio, Mirko
    Pederzoli, Paolo
    Falconi, Massimo
    AMERICAN JOURNAL OF SURGERY, 2012, 203 (02): : 132 - 139
  • [37] Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer
    Stoop, Thomas F.
    Theijse, Rutger T.
    Seelen, Leonard W. F.
    Koerkamp, Bas Groot
    van Eijck, Casper H. J.
    Wolfgang, Christopher L.
    van Tienhoven, Geertjan
    van Santvoort, Hjalmar C.
    Molenaar, I. Quintus
    Wilmink, Johanna W.
    Del Chiaro, Marco
    Katz, Matthew H. G.
    Hackert, Thilo
    Besselink, Marc G.
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2024, 21 (02) : 101 - 124
  • [38] Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer
    Ji Hun Kang
    Seung Soo Lee
    Jin Hee Kim
    Jae Ho Byun
    Hyoung Jung Kim
    Changhoon Yoo
    Kyu-pyo Kim
    Baek-Yeol Ryoo
    Song Cheol Kim
    European Radiology, 2021, 31 : 864 - 874
  • [39] Current status and future perspective of neoadjuvant therapy in locally advanced and borderline resectable pancreatic adenocarcinoma: a narrative review
    Hyung, Jaewon
    Lee, Sang Soo
    Hwang, Dae Wook
    Park, Jin-Hong
    Kim, Kyu-Pyo
    Yoo, Changhoon
    CHINESE CLINICAL ONCOLOGY, 2022, 11 (03)
  • [40] Prediction of Early Distant Recurrence in Upfront Resectable Pancreatic Adenocarcinoma: A Multidisciplinary, Machine Learning-Based Approach
    Palumbo, Diego
    Mori, Martina
    Prato, Francesco
    Crippa, Stefano
    Belfiori, Giulio
    Reni, Michele
    Mushtaq, Junaid
    Aleotti, Francesca
    Guazzarotti, Giorgia
    Cao, Roberta
    Steidler, Stephanie
    Tamburrino, Domenico
    Spezi, Emiliano
    Del Vecchio, Antonella
    Cascinu, Stefano
    Falconi, Massimo
    Fiorino, Claudio
    De Cobelli, Francesco
    CANCERS, 2021, 13 (19)